Prevention of hypertension and associated cardiovascular disease. A 1995 statement. Conclusions from a joint WHO/ISH Meeting. Clinical & Experimental Hypertension (New York) 1996; 18(New York):581–593.
From the Centers for Disease Control. Public health focus: effectiveness of smoking-control strategies—United States. JAMA 1992; 268(13):1645–1646.
Getting employees to say no … to smoking. Bus Health 1993; 11 (3):42–4, 46.
Public health focus: effectiveness of smoking-control strategies—United States. MMWR - Morbidity & Mortality Weekly Report 1992; 41(35):645–647.
Asthma: the role of fluticasone propionate. Br J Hosp Med 1998; 58(11):555–564.
Control of hereditary diseases. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1996; 865:1–84.
Disease management programs: benchmarking costs, savings, ROI. Healthcare Benchmarks 1998; 5(8):117–119.
Path inventory facilitates benchmarking care paths. Healthcare Benchmarks 1997; 4(11):159–161.
Abdul-Mohsen MF, al Quorain A, al Hamdan AA, Husain A, Qutub H, Ladipo GO. Clinical profile of patients admitted to the coronary care unit with possible myocardial infarction without diagnostic ECG and/or enzyme changes. East Afr Med J 1993; 70(12):777–781.
Agrez MV, Coory M, Cockburn J. Population screening for colorectal carcinoma with fecal-occult blood testing: are we sufficiently informed? Cancer 1998; 82(10):1803–1807.
Allison JE. Review article: faecal occult blood testing for colorectal cancer. Alimentary Pharmacology & Therapeutics 1998; 12(1):1–10.
Anania G, Bazzocchi M, di Loreto C, Risaliti A, Terrosu G, Donini A et al. Percutaneous large core needle biopsy versus surgical biopsy in the diagnosis of breast lesions. Int Surg 1997; 82(1):52–55.
Anthony D. Immediate breast reconstruction following mastectomy for cancer of the breast. Bristol, England: U K National Health Service, South and West Regional Health Authority, 1995; 1995:19.
Antman EM, Seelig MS, Fleischmann K, Lau J, Kuntz K, Berkey CS et al. Magnesium in acute myocardial infarction: scientific, statistical, and economic rationale for its use. Cardiovasc Drugs Ther 1996; 10(3):297–301.
Anwar S, Hall C, Elder JB. Screening for colorectal cancer: present, past and future. European Journal of Surgical Oncology 1998; 24(6):477–486.
Arroll B. Screening: the double edged sword! N Z Med J 1990; 103(894):346–348.
Badgett RG, Tanaka DJ. Is screening for chronic obstructive pulmonary disease justified? Preventive Medicine 1997; 26(4):466–472.
Bains N, Pickett W, Hoey J. The use and impact of incentives in population-based smoking cessation programs: a review. American Journal of Health Promotion 1998; 12(5):307–320.
Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS et al. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. Am J Cardiol 1995; 76(14):1007–1013.
Barnes NC, Thwaites RM, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respiratory Medicine 1999; 93(6):402–407.
Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102(4 Pt 1):531–538.
Barthel W, Haustein KO. Cost-benefit analysis—a prerequisite of a rational pharmacotherapy in cardiovascular diseases. Timely thrombolysis in the acute myocardial infarction. Int J Clin Pharmacol Ther 1996; 34(7):277–281.
Baur X, Chen Z, Liebers V. Exposure-response relationships of occupational inhalative allergens. Clin Exp Allergy 1998; 28(5):537–544.
Beatt KJ, Fath-Ordoubadi F. Angioplasty for the treatment of acute myocardial infarction. Heart 1997; 78 Suppl 2:12–15.
Bjornson-Benson WM, Stibolt TB, Manske KA, Zavela KJ, Youtsey DJ, Buist AS. Monitoring recruitment effectiveness and cost in a clinical trial. Controlled Clinical Trials 1993; 14(2 Suppl):52S–67S.
Blaiss MS. Outcomes analysis in asthma. JAMA 1997; 278(22):1874–1880.
Blake GH, DeHart RL. Clinical preventive medicine in business and industry: the economic impact. J Health Soc Policy 1994; 6(1):59–70.
Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Annals of Allergy, Asthma, & Immunology 1998; 80(2):189–194.
Boersma H, van der Vlugt MJ, Arnold AE, Deckers JW, Simoons ML. Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. Eur Heart J 1996; 17(1):64–75.
Bolin TD. Cost benefit of early diagnosis of colorectal cancer. Scandinavian Journal of Gastroenterology - Supplement 1996; 220:142–146.
Bond JH. Fecal occult blood testing for colorectal cancer. Can we afford not to do this? Gastroenterology Clinics of North America 1997; 26(1):57–70.
Bourke JP, Richards DA, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991; 18(3):780–788.
Breuninger K. The utility of flexible sigmoidoscopy as a screening tool for colon cancer. J Am Acad Nurse Pract 1996; 8(9):431–432.
Brown AD, Garber AM. Cost effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics 1998; 14(1):27–48.
Brown DC. Smoking cessation in pregnancy. Canadian Family Physician 1996; 42:102–105.
Brown ML, Kessler LG. Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? Int J Cancer 1996; 69(1):55–57.
Bry JD, Belkin M, O'Donnell TF, Jr., Mackey WC, Udelson JE, Schmid CH et al. An assessment of the positive predictive value and cost-effectiveness of dipyridamole myocardial scintigraphy in patients undergoing vascular surgery. J Vasc Surg 1994; 19(1):112–121.
Bukstein DA. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol. American Journal of Managed Care 1997; 3(11):1701–1706.
Bussey HI, Chiquette E. Costs of oral anticoagulation treatment after myocardial infarction. JAMA 1995; 274(20):1588–1589.
Byers T, Gorsky R. Estimates of costs and effects of screening for colorectal cancer in the United States. Cancer 1992; 70(5 Suppl):1288–1295.
Cady B. Cost-effective preoperative evaluation, operative treatment, and postoperative follow-up in the breast cancer patient. Surgical Clinics of North America 1996; 76(1):25–34.
Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 1995; 273(12):965–967.
Campbell S. New AHCPR guideline targets and cost of smoking cessation programs. Health Care Strategic Management 1996; 14(6):16–17.
Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994; 14(3):259–265.
Carpenter CR. Promoting tobacco cessation in the military: an example for primary care providers. Military Medicine 1998; 163(8):515–518.
Chapman KR, Dales RE, Chan-Yeung M, Cote J. Future research in asthma education. Chest 1994; 106(4 Suppl):270S–273S.
Ciatto S, Rosselli DT, Ambrogetti D, Bravetti P, Catarzi S, Morrone D et al. Solid nonpalpable breast lesions. Success and failure of guided fine-needle aspiration cytology in a consecutive series of 2444 cases. Acta Radiol 1997; 38(5):815–820.
Clark AB, Holt JM. Identifying and managing patients with hyperlipidemia. Am J Manag Care 1997; 3(8):1211–1219.
Cockburn J, Ruth D, Silagy C, Dobbin M, Reid Y, Scollo M et al. Randomised trial of three approaches for marketing smoking cessation programmes to Australian general practitioners. BMJ 1992; 304(6828):691–694.
Cohen DR, Fowler GH. Economic implications of smoking cessation therapies: a review of economic appraisals. Pharmacoeconomics 1993; 4(5):331–344.
Cohn JR, Caliguiri LA, Gallagher PE, Schenkel EJ. Commentary: prevention and cost of asthma—a model for cost effective health care. Allergy Proc 1994; 15(1):39–41.
Cole RE, Wagner DE. The pros and cons of a mass-media colorectal screening program. Prog Clin Biol Res 1990; 339:325–330.
Compas BE, Haaga DA, Keefe FJ, Leitenberg H, Williams DA. Sampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer, and bulimia nervosa. J Consult Clin Psychol 1998; 66(1):89–112.
Crealey GE, McElnay JC, Maguire TA, O'Neill C. Costs and effects associated with a community pharmacy-based smoking-cessation programme. Pharmacoeconomics 1998; 14(3):323–333.
Croghan IT, Offord KP, Evans RW, Schmidt S, Gomez-Dahl LC, Schroeder DR et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clinic Proceedings 1997; 72(10):917–924.
Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. New England Journal of Medicine 1998; 339(10):673–679.
Davis R, McTavish D. Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma. Pharmacoeconomics 1995; 7(5):457–470.
Demoly P, Chung KF. Pharmacology of corticosteroids. Respir Med 1998; 92(3):385–394.
Donald JJ, Burhenne HJ. Colorectal cancer. Can we lower the death rate in the 1990s? Canadian Family Physician 1993; 39:107–114.
Donaldson C. Economic evaluation: an ethical imperative? Inflammatory Bowel Diseases 1998; 4(1):40–44.
Donovan JM, Syngal S. Colorectal cancer in women: an underappreciated but preventable risk. Journal of Womens Health 1998; 7(1):45–48.
Dunbabin D. Cost-effective intervention in stroke. Pharmacoeconomics 1992; 2(6):468–499.
Early DS, Marshall JB. Is routine screening for colorectal cancer justifiable? These gastroenterologists say YES. Postgraduate Medicine 1997; 102(1):48–52.
Eddy DM. Clinical decision making: from theory to practice. Cost-effectiveness analysis. Is it up to the task? JAMA 1992; 267(24):3342–3348.
Effron MB, Morales RE. Thrombolytic therapy for acute myocardial infarction in the 1990s. Md Med J 1991; 40(6):485–491.
Ehleben CM, Winters PM, Wheeler CJ, Shlaer SM. Evaluation of a colorectal cancer screening program. Prog Clin Biol Res 1990; 339:351–360.
Eisenstein EL, Mark DB, Califf RM. Importance of cost and quality of life in decisions about routine angiography after acute myocardial infarction. The role of cost- effectiveness models. Circulation 1996; 94(5):869–871.
Elixhauser A. The costs of smoking and the cost effectiveness of smoking-cessation programs. J Public Health Policy 1990; 11(2):218–237.
Erfurt JC, Foote A, Heirich MA. The cost-effectiveness of work-site wellness programs for hypertension control, weight loss, and smoking cessation. Journal of Occupational Medicine 1991; 33(9):962–970.
Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275(12):913–918.
Escudero AI, Sanchez-Guerrero IM, Mora AM, Soriano V, Lopez JD, Garcia FJ et al. Cost-effectiveness of various methods of diagnosing hypersensitivity to Alternaria. Allergologia et Immunopathologia 1993; 21(4):153–157.
Evans R, LeBailly S, Gordon KK, Sawyer A, Christoffel KK, Pearce B. Restructuring asthma care in a hospital setting to improve outcomes. Chest 1999; 116(4 Suppl 1):210S–216S.
Every NR, Parsons LS, Fihn SD, Larson EB, Maynard C, Hallstrom AP et al. Long-term outcome in acute myocardial infarction patients admitted to hospitals with and without on-site cardiac catheterization facilities. MITI Investigators. Myocardial Infarction Triage and Intervention. Circulation 1997; 96(6):1770–1775.
Faivre J, Tazi MA, Autier P, Bleiberg H. Should there be mass screening using faecal occult blood tests for colorectal cancer? European Journal of Cancer 1998; 34(6):773–780.
Fallen EL, Cairns J, Dafoe W, Frasure-Smith N, Genest J, Jr., Massel D et al. Management of the postmyocardial infarction patient: a consensus report–revision of 1991 CCS guidelines. Can J Cardiol 1995; 11(6):477–486.
Fath-Ordoubadi F, Beatt KJ. Angioplasty and acute myocardial infarction. Lancet 1993; 342(8875):861–862.
Fenn P, Gray AM, McGuire A. The cost-effectiveness of thrombolytic therapy following acute myocardial infarction. Br J Clin Pract 1991; 45(3):181–184.
Fletcher RH. Should all people over the age of 50 have regular fecal occult-blood tests? If it works, why not do it? New England Journal of Medicine 1998; 338(16):1153–4discussion.
Folgering H, Rooyakkers J, Herwaarden C. Education and cost/benefit ratios in pulmonary patients. Monaldi Arch Chest Dis 1994; 49(2):166–168.
Franzosi MG, Maggioni AP, Santoro E, Tognoni G, Cavalieri E. Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. Pharmacoeconomics 1998; 13(3):337–346.
Frisell J, Lidbrink E. The Stockholm Mammographic Screening Trial: Risks and benefits in age group 40–49 years. J Natl Cancer Inst Monogr 1997;(22):49–51.
Gal R, Ahmad M. Cost-saving approach to normal technetium-99m sestamibi myocardial perfusion scan. Am J Cardiol 1996; 78(9):1047–1049.
Garvican L. Planning for a possible national colorectal cancer screening programme. Journal of Medical Screening 1998; 5(4):187–194.
Gelfand DW. Colorectal cancer. Screening strategies. Radiologic Clinics of North America 1997; 35(2):431–438.
Gelfand DW, Ott DJ. The economic implications of radiologic screening for colonic cancer. AJR Am J Roentgenol 1991; 156(5):939–943.
Gelfand DW. Screening for colon cancer: economics and related considerations. Seminars in Roentgenology 1996; 31(2):170–176.
Gelfand DW, Ott DJ. Colon cancer screening: where radiology fits in. Diagn Imaging (San Franc) 1993; 15(7):75–77.
Gergen PJ, Goldstein RA. Does asthma education equal asthma intervention? International Archives of Allergy & Immunology 1995; 107(1–3):166–168.
Gianetti J, Gensini G, De Caterina R. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy—equivalence of costs as a possible case for oral anticoagulants. Thromb Haemost 1998; 80(6):887–893.
Gillis JC, Wagstaff AJ, Goa KL. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 1995; 50(1):102–136.
Glynn TJ, Manley MW, Pechacek TF. Physician-initiated smoking cessation program: the National Cancer Institute trials. Prog Clin Biol Res 1990; 339:11–25.
Goa KL, Balfour JA, Zuanetti G. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52(4):564–588.
Goldman LK, Glantz SA. Evaluation of antismoking advertising campaigns. JAMA 1998; 279(10):772–777.
Goodnough LT, Monk TG. Evolving concepts in autologous blood procurement and transfusion: case reports of perisurgical anemia complicated by myocardial infarction. Am J Med 1996; 101(2A):33S–37S.
Gourlay S. The pros and cons of transdermal nicotine therapy. Medical Journal of Australia 1994; 160(3):152–159.
Greenwald P, Stern HR. Role of biology and prevention in aerodigestive tract cancers. Journal of the National Cancer Institute Monographs (13):3–14, 1992; 1992.(13).
Gruffydd-Jones K. Quality-of-life measures in asthma—do they matter to the GP? British Journal of General Practice 1997; 47(419):392–394.
Gyrd-Hansen D, Sogaard J, Kronborg O. Colorectal cancer screening: efficiency and effectiveness. Health Economics 1998; 7(1):9–20.
Haddow JE, Knight GJ, Kloza EM, Palomaki GE, Wald NJ. Cotinine-assisted intervention in pregnancy to reduce smoking and low birthweight delivery. Br J Obstet Gynaecol 1991; 98(9):859–865.
Haigh R, Castleden M, Woods K, Fletcher S, Bowns I, Gibson M et al. Management of myocardial infarction in the elderly: admission and outcome on a coronary care unit. Health Trends 1991; 23(4):154–157.
Hardcastle JD, Robinson MH. Screening for colorectal cancer. European Journal of Cancer 1992; 28A(11):1778–1780.
Hays JT, Dale LC, Hurt RD, Croghan IT. Trends in smoking-related diseases. Why smoking cessation is still the best medicine. Postgraduate Medicine 1998; 104(6):56–62.
Heine JA, Rothenberger DA. Cost-effective management of colon and rectal cancer. World J Surg 1991; 15(5):597–604.
Heinen L, Peterson E, Pion K, Leatherman S. Quality evaluation in a managed care system: comparative data to assess health plan performance. Managed Care Quarterly 1993; 1(1):62–76.
Hilleman DE, Lucas BD, Jr., Mohiuddin SM, Holmberg MJ. Cost-minimization analysis of intravenous adenosine and dipyridamole in thallous chloride TI 201 SPECT myocardial perfusion imaging. Ann Pharmacother 1997; 31(9):974–979.
Hillner BE. Decision analysis: MIBI imaging of nonpalpable breast abnormalities. J Nucl Med 1997; 38(11):1772–1778.
Hillner BE, Bear HD, Fajardo LL. Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: a decision analysis model. Academic Radiology 1996; 3(4):351–360.
Hillner BE, Smith TJ. Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. Oncology 1995; 9(11 Suppl):129–134.
Hillner BE. Economic and cost-effectiveness issues in breast cancer treatment. Semin Oncol 1996; 23(1 Suppl 2):98–104.
Hines D. Young smokers' attitudes about methods for quitting smoking: barriers and benefits to using assisted methods. Addictive Behaviors 1996; 21(4):531–535.
Hlatky MA, Owens DK. Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. J Am Coll Cardiol 1998; 31(7):1490–1492.
Hu TW, Sung HY, Keeler TE. The state antismoking campaign and the industry response: the effects of advertising on cigarette consumption in California. American Economic Review 1995; 85(2):85–90.
Huckell VF, Bernstein V, Crowell R, Dagenais GR, Higginson LA, Isserow S et al. Angiotensin-converting enzyme inhibition in myocardial infarction—Part 2: Clinical issues and controversies. Can J Cardiol 1997; 13(2):173–182.
Hughes JR. The future of smoking cessation therapy in the United States. Addiction 1996; 91(12):1797–1802.
Iunes RF. On the economic analysis of response to preventive measures. Revista de Saude Publica 1991; 25(4):243–250.
Jaffe AS. More rapid biochemical diagnosis of myocardial infarction: necessary? Prudent? Cost effective? Clin Chem 1993; 39(8):1567–1569.
Jamali FR, Kurtzman SH, Deckers PJ. Role of axillary dissection in mammographically detected breast cancer. Surgical Oncology Clinics of North America 1997; 6(2):343–358.
Jednak MA, Nostrant TT. Screening for colorectal cancer. Primary Care 1998; Clinics in Office Practice.;25(2):293–308.
Katelaris CH. Successful immunotherapy. A partnership between consultant and general practitioner. Aust Fam Physician 1998; 27(8):687–692.
Kazzaz Y, Levey S, McKnight M, Schnitzler MA. Opportunities for potential cost saving in the management of acute myocardial infarction. Best Pract Benchmarking Healthc 1997; 2(4):178–182.
Kellett J, Clarke J. Comparison of “accelerated” tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction. Med Decis Making 1995; 15(4):297–310.
Korhonen HJ, Niemensivu H, Piha T, Koskela K, Wiio J, Johnson CA et al. National TV smoking cessation program and contest in Finland. Preventive Medicine 1992; 21(1):74–87.
Krahn M. Issues in the cost-effectiveness of asthma education. Chest 1994; 106(4 Suppl):264S–269S.
Krishnamoorthy M, Mintz A, Liem T, Applebaum H. Diagnosis and treatment of respiratory symptoms of initially unsuspected gastroesophageal reflux in infants. Am Surg 1994; 60(10):783–785.
Kronborg O, Wahrendorf J. Colorectal cancer screening: methods, benefits and costs. European Journal of Cancer 1994; 30A(6):877–879.
Kronborg O. Population screening for colorectal cancer, the goals and means. Annals of Medicine 1991; 23(4):373–379.
Krumholz HM, Chen J, Murillo JE, Cohen DJ, Radford MJ. Clinical correlates of in-hospital costs for acute myocardial infarction in patients 65 years of age and older. Am Heart J 1998; 135(3):523–531.
Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. Progress in Cardiovascular Diseases 1995; 37(4):243–271.
Kwon AH, Yamada O, Uetsuji S, Matsui Y, Kamiyama Y. Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 1997; 7(3):223–227.
Labott SM, Preisman RC, Popovich JJ, Iannuzzi MC. Health care utilization of somatizing patients in a pulmonary subspecialty clinic. Psychosomatics 1995; 36(2):122–128.
Lambert R. Role of endoscopy in the prevention of digestive cancer: application to colorectal cancer. Endoscopy 1998; 30(7):628–640.
Lando HA, Loken B, Howard-Pitney B, Pechacek T. Community impact of a localized smoking cessation contest. Am J Public Health 1990; 80(5):601–603.
Laupacis A, Labelle R, Goeree R, Cairns J. The cost-effectiveness of routine post myocardial infarction exercise stress testing. Can J Cardiol 1990; 6(4):157–163.
Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Archives of Internal Medicine 1995; 155(18):1933–1941.
Lickteig S, Knutson D, Yoast R, Remington PL. Wisconsin's experience with the national nicotine patch giveaway. Wisconsin Medical Journal 1993; 92(11):631–632.
Lieberman D. How to screen for colon cancer. Annu Rev Med 1998; 49:163–172.
Lieberman D, Sleisenger MH. Is it time to recommend screening for colorectal cancer? Lancet 1996; 348(9040):1463–1464.
Lieberman D. Cost-effectiveness of colon cancer screening. Am J Gastroenterol 1991; 86(12):1789–1794.
Lieu TA, Quesenberry CP, Sorel ME, Mendoza GR, Leong AB. Computer-based models to identify high-risk children with asthma. American Journal of Respiratory & Critical Care Medicine 1998; 157(4 Pt 1):1173–1180.
Liljas B, Lahdensuo A. Is asthma self-management cost-effective? Patient Educ Couns 1997; 32(1 Suppl):S97–104.
Loo R. Policies and procedures in the workplace: how health care organizations compare. Healthc Manag Forum 1993; 6(2):39–43.
Lum DF, Welton ML. Benign colorectal polyps. Endoscopic surveillance guidelines and effects on colorectal cancer risk. Surgical Oncology Clinics of North America 1996; 5(3):621–632.
Lusk SL. Health promotion and disease prevention in the worksite. Annual Review of Nursing Research 1997; 15:187–213.
Magid DJ, Koepsell TD, Every NR, Martin JS, Siscovick DS, Wagner EH et al. Absence of association between insurance copayments and delays in seeking emergency care among patients with myocardial infarction. N Engl J Med 1997; 336(24):1722–1729.
Mamlok R. A cost-effective approach to the diagnosis and treatment of the wheezing infant. Allergy Asthma Proc 1997; 18(3):149–152.
Mantovani LG, Belisari A, Szucs TD. Captopril in the management of patients after acute myocardial infarctions. A cost effectiveness analysis in Italy. Pharmacol Res 1998; 37(5):345–351.
Markowitz AJ, Winawer SJ. Screening and surveillance for colorectal carcinoma. Hematology - Oncology Clinics of North America 1997; 11(4):579–608.
Maron DJ. Nonlipid primary and secondary prevention strategies for coronary heart disease [published erratum appears in Clin Cardiol 1996 Jul;19(7):602]. Clinical Cardiology 1919; 19(5):419–423.
Massie RJ, Mellis CM. The economic aspects of drug delivery in asthma. Pharmacoeconomics 1997; 11(5):398–407.
Matallana RH. Comprehensive breast diagnosis. European Journal of Gynaecological Oncology 1993; 14(4):292–295.
Mazur L, Miller J, Fox L, Howland R. Variation in the process of pediatric asthma care. Journal for Healthcare Quality 1996; 18(3):11–17.
McClure JB, Skaar K, Tsoh J, Wetter DW, Cinciripini PM, Gritz ER. Smoking cessation. 3: Needed healthcare policy changes. Behavioral Medicine 1997; 23(1):29–34.
McGlynn EA. Choosing chronic disease measures for HEDIS: conceptual framework and review of seven clinical areas. Managed Care Quarterly 1996; 4(3):54–77.
McMurray JJ, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post- myocardial infarction. Eur Heart J 1997; 18(9):1411–1415.
Meduri GU. Noninvasive positive-pressure ventilation in patients with acute respiratory failure. Clin Chest Med 1996; 17(3):513–553.
Meenan RT, Stevens VJ, Hornbrook MC, La Chance PA, Glasgow RE, Hollis JF et al. Cost-effectiveness of a hospital-based smoking cessation intervention. Medical Care 1998; 36(5):670–678.
Milne RJ. Evaluation of the pharmacoeconomic literature. Pharmacoeconomics 1994; 6(4):337–345.
Molken MP, van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980–1991. Soc Sci Med 1992; 35(2):161–175.
Morrow M. When can stereotactic core biopsy replace excisional biopsy?—A clinical perspective. Breast Cancer Res Treat 1995; 36(1):1–9.
Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993; 9(6):553–558.
Nelson RL. Screening of average-risk individuals for colorectal cancer and postoperative evaluation of patients with colorectal cancer. Surgical Clinics of North America 1996; 76(1):35–45.
Nightingale CH. Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma. Pharmacotherapy 1995; 15(5):677–681.
Niv Y. Does a risk questionnaire add anything to a colorectal screening project? Report of a 3-year screening experience. Journal of Clinical Gastroenterology 1992; 15(1):33–36.
Niv Y, Gold B, Fraser GM. Screening for colonic neoplastic lesions using flexible sigmoidoscopy in employees of a nuclear research center and members of collective settlements. Isr J Med Sci 1996; 32(12):1167–1172.
Norum J. Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy. Annals of Oncology 1998; 9(6):613–618.
O'Brien KP. Asthma in the managed care setting. Current Opinion In Pulmonary Medicine 1997; 3(1):56–60.
O'Brien KP. Managed care and the treatment of asthma. J Asthma 1995; 32(5):325–334.
Oldridge NB. Cardiac rehabilitation and risk factor management after myocardial infarction. Clinical and economic evaluation. Wien Klin Wochenschr Suppl 1997; 2:6–16.
Oliveira M, Staunton A, Camm AJ, Malik M. Stepwise strategy on the cost of risk stratification after acute myocardial infarction: a retrospective simulation study. Pacing Clin Electrophysiol 1998; 21(3):603–609.
Ostro B, Chestnut L. Assessing the health benefits of reducing particulate matter air pollution in the United States. Environmental Research 1998; 76(2):94–106.
Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21(10):1479–1486.
Parikh HK, Badwe RA, Ash CM, Hamed H, Freitas RJ, Chaudary MA et al. Early drain removal following modified radical mastectomy: a randomized trial. Journal of Surgical Oncology 1992; 51(4):266–269.
Pashkow P, Ades PA, Emery CF, Frid DJ, Houston-Miller N, Peske G et al. Outcome measurement in cardiac and pulmonary rehabilitation. AACVPR Outcomes Committee. American Association of Cardiovascular and Pulmonary Rehabilitation. Journal of Cardiopulmonary Rehabilitation 1995; 15(6):394–405.
Patterson R, De Swarte RD, Grammer LC, Greenberger PA, Harris KE, McGrath K et al. Evolution of patient care, education, and research in asthma by one academic team of investigators over 35 years: the Northwestern University Medical School Division of Allergy-Immunology experience (Part Two). Allergy Proceedings 1994; 15(4):223–232.
Paul CL, Sanson-Fisher RW. Experts' agreement on the relative effectiveness of 29 smoking reduction strategies. Preventive Medicine 1996; 25(5):517–526.
Pearce MJ, Begg EJ. Encouraging consensus cost effective drug therapy: five years experience with a hospital drug utilisation review programme. N Z Med J 1997; 110(1040):92–95.
Pelc A, Dardenne J, Frelon JH, Hanania G. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting. Pharmacoeconomics 1997; 11(6):595–605.
Peters DH, Benfield P. Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy [published erratum appears in Pharmacoeconomics 1995 Jun;7(6):554]. Pharmacoeconomics 1994; 6(4):370–400.
Peters DH, Faulds D. Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma. Pharmacoeconomics 1995; 7(6):562–574.
Pettine S, Place R, Babu S, Williard W, Kim D, Carter P. Stereotactic breast biopsy is accurate, minimally invasive, and cost effective. Am J Surg 1996; 171 (5):474–476.
Pharoah PD, Sanderson SP. Health promotion in primary care: modelling the impact of intervention on coronary heart disease and stroke. Journal of Public Health Medicine 1995; 17(2):150–156.
Phillips CJ, Prowle MJ. Economics of a reduction in smoking: case study from Heartbeat Wales. Journal of Epidemiology & Community Health 1993; 47(3):215–223.
Plans-Rubio P. Cost-effectiveness of cardiovascular prevention programs in Spain. International Journal of Technology Assessment in Health Care 1998; 14(2):320–330.
Playford DA, Watts GF. Management of lipid disorders in the elderly. Drugs Aging 1997; 10(6):444–462.
Por CP, Evans MF. Peak flow meters for asthma patients. Do they up the benefits or up the costs? Canadian Family Physician 1998; 44:1265–1267.
Prager D, Grundfest-Broniatowski S, Lerner HJ, Margolese RG, Dimitrov N, Silverman P. Breast cancer: are imaging studies cost effective following breast cancer and adjuvant therapy? Seminars in Oncology 1995; 22(4):xiii–xixx.
Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Respiratory Medicine 1998; 92(2):351–353.
Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Respiratory Medicine 1998; 92(11):1302–1304.
Provenzale D, Lipscomb J. Cost-effectiveness: definitions and use in the gastroenterology literature. American Journal of Gastroenterology 1996; 91(8):1488–1493.
Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Annals of Internal Medicine 1997; 126(10):811–822.
Ratcliffe J, Cairns J, Platt S. Cost effectiveness of a mass media-led anti-smoking campaign in Scotland. Tob Control 1997; 6(2):104–110.
Reid D. Tobacco control: overview. British Medical Bulletin 1996; 52(1):108–120.
Richards JMJ, Hemstreet MP. Measures of life quality, role performance, and functional status in asthma research. Am J Respir Crit Care Med 1994; 149(2 Pt 2):S31–S39.
Rigby K, Silagy C, Crockett A. Can resource use be extracted from randomized controlled trials to calculate costs? A review of smoking cessation interventions in general practice. International Journal of Technology Assessment in Health Care 1996; 12(4):714–720.
Robinson MB, Thompson E, Black NA. A model for estimating the cost-utility of clinical audit. The example of thrombolysis for suspected acute myocardial infarction. Int J Technol Assess Health Care 1998; 14(1):161–171.
Robinson MB, Thompson E, Black NA. Why is evaluation of the cost effectiveness of audit so difficult? The example of thrombolysis for suspected acute myocardial infarction. Qual Health Care 1998; 7(1):19–26.
Robinson MH, Hardcastle JD. Should we be screening for colorectal cancer? British Medical Bulletin 1998; 54(4):807–821.
Rohl BJ, Meyer LC, Lung CL. Patient-centered asthma care: a community-based multidisciplinary model. Medical Interface 1994; 7(1):48–50.
Rubin M, Horiuchi K, Joy N, Haun W, Read R, Ratzer E et al. Use of fine needle aspiration for solid breast lesions is accurate and cost-effective. Am J Surg 1997; 174(6):694–696.
Rutherford JD. Risk stratification after myocardial infarction in the thrombolytic era. Curr Opin Cardiol 1996; 11(4):428–433.
Schadlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 1998; 14(6):653–669.
Schauffler HH, Parkinson MD. Health insurance coverage for smoking cessation services. Health Education Quarterly 1920; 20(2):185–206.
Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma 1998; 35(6):455–472.
Schultz LF, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. Journal of the American Academy of Dermatology 1996; 34(5 Pt 1):760–764.
Schultz MA, van Servellen G, Chang BL, McNeese-Smith D, Waxenberg E. The relationship of hospital structural and financial characteristics to mortality and length of stay in acute myocardial infarction patients. Outcomes Manag Nurs Pract 1998; 2(3):130–136.
Self T, Nolan S. Long-term management of asthma: how to improve outcomes. American Journal of Managed Care 1997; 3(9):1425–38quiz.
Severson HH, Andrews JA, Lichtenstein E, Wall M, Akers L. Reducing maternal smoking and relapse: long-term evaluation of a pediatric intervention. Preventive Medicine 1997; 26(1):120–130.
Shumaker SA, Brooks MM, Schron EB, Hale C, Kellen JC, Inkster M et al. Gender differences in health-related quality of life among postmyocardial infarction patients: brief report. CAST Investigators. Cardiac Arrhythmia Suppression Trials. Womens Health 1997; 3(1):53–60.
Slevin ML. Quality of life: philosophical question or clinical reality? BMJ 1992; 305(6851):466–469.
Smeeth L, Fowler G. Nicotine replacement therapy for a healthier nation. Nicotine replacement is cost effective and should be prescribable on the NHS. BMJ 1998; 317(7168):1266–1267.
Smith MD, McGhan WF. Attacking expenditures for asthma. Business & Health 1997; 15(4):67–68.
Soo MS. Imaging-guided core biopsies in the breast. South Med J 1998; 91(11):994–1000.
Stern HS. Technologic and economic considerations of three old, yet new, imaging procedures. Academic Radiology 1996; 3 Suppl 1:S147–S149.
Stevermer J. Cost-effectiveness of the nicotine patch. Journal of Family Practice 1996; 43(2):125–126.
Sullivan S, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. American Journal of Respiratory & Critical Care Medicine 1996; 154(3 Pt 2):S84–S95.
Sullivan SD, Weiss KB. Assessing cost-effectiveness in asthma care: building an economic model to study the impact of alternative intervention strategies. Allergy 1993; 48(17 Suppl):146–52discussion.
Tannock IF, Belanger D. Use of a physician-directed questionnaire to define a consensus about management of breast cancer: implications for assessing costs and benefits of treatment. J Natl Cancer Inst Monogr 1992;(11):137–142.
Tillgren P, Rosen M, Haglund BJ, Ainetdin T, Lindholm L, Holm LE. Cost–effectiveness of a tobacco 'quit and win' contest in Sweden. Health Policy 1993; 26(1):43–53.
Towler B, Irwig L, Glasziou P, Haas M, Plunkett A, Salkeld G. The potential benefits and harms of screening for colorectal cancer. Australian Journal of Public Health 1995; 19(1):24–28.
Tsevat J. Impact and cost-effectiveness of smoking interventions. American Journal of Medicine 1992; 93(1A):43S–47S.
Turner-Boutle M, Sheldon T, Smith GD, Ebrahim S. On the evidence. Cholesterol and coronary heart disease screening & treatment. Health Service Journal 1998; 108(5593):36–37.
Ubel PA, DeKay ML, Baron J, Asch DA. Cost-effectiveness analysis in a setting of budget constraints—is it equitable? N Engl J Med 1996; 334(18):1174–1177.
Van Dam J, Bond JH, Sivak MVJ. Fecal occult blood screening for colorectal cancer. Archives of Internal Medicine 1995; 155(22):2389–2402.
Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998; 82(9):1632–1637.
Verani MS. Diagnosis and management of acute myocardial infarction. J Nucl Cardiol 1997; 4(2 Pt 2):S158–S163.
Vogt TM, Hollis JF, Lichtenstein E, Stevens VJ, Glasgow R, Whitlock E. The medical care system and prevention: the need for a new paradigm. Hmo Practice 1998; 12(1):5–13.
Voss GB, Hasman A, Rutten F, de Zwaan C, Carpay JJ. Explaining cost variations in DRGs 'Acute Myocardial Infarction' by severity of illness. Health Policy 1994; 28(1):37–50.
Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Annals of Internal Medicine 1991; 115(10):807–817.
Wait SH. Economic evaluation of endocrine therapy in the treatment of breast cancer. Anticancer Drugs 1998; 9(10):849–857.
Walker A, Whynes DK. Participation and screening programmes for colorectal cancer: more would be better? Journal of Health Economics 1991; 10(2):207–225.
Wallace JE, Sayler C, McDowell NG, Moseley HS. The role of stereotactic biopsy in assessment of nonpalpable breast lesions. Am J Surg 1996; 171(5):471–473.
Warner KE. Smoking out the incentives for tobacco control in managed care settings. Tobacco Control 1998; 7 Suppl:S50–S54.
Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence- and implications for coverage. Pharmacoeconomics 1997; 11(6):538–549.
Warnock N. Developments in radiology: techniques new, refined and revisited. Iowa Medicine 1993; 83(8):299–301.
Weiss K. The impact of pharmacologic therapy on the costs of asthma. Allergy Proc 1994; 15(4):189–192.
Weiss KB, Sullivan SD. Socio-economic burden of asthma, allergy, and other atopic illnesses. Pediatric Allergy & Immunology 1994; 5(6 Suppl):7–12.
Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. Pharmacoeconomics 1993; 4(1):14–30.
Weissman IA, Dickinson CZ, Dworkin HJ, O'Neill WW, Juni JE. Cost-effectiveness of myocardial perfusion imaging with SPECT in the emergency department evaluation of patients with unexplained chest pain. Radiology 1996; 199(2):353–357.
West JA. Cost-effective strategies for the management of vascular disease. Vasc Med 1997; 2(1):25–29.
Weston MW. Comparison of costs and charges for fluoroscopic- and echocardiographic- guided endomyocardial biopsy. Am J Cardiol 1994; 74(8):839–840.
Whynes DK, Walker AR, Chamberlain JO, Hardcastle JD. Screening and the costs of treating colorectal cancer. Br J Cancer 1993; 68(5):965–968.
Wilkinson P, Stevenson R, Ranjadayalan K, Marchant B, Roberts R, Timmis AD. Early discharge after acute myocardial infarction: risks and benefits. Br Heart J 1995; 74(1):71–75.
Wilson SR. Individual versus group education: is one better? Patient Educ Couns 1997; 32(1 Suppl):S67–S75.
Windsor RA, Boyd NR. The impact of dissemination of smoking cessation methods on health care costs among pregnant Medicaid recipients. In: Toward the year 2000; 2000:refining-21.
Witmer DR, Dickson-Witmer D, Teixido R. Initial 100 consecutive stereotactic core breast biopsies in a private breast center setting. Del Med J 1997; 69(6):297–301.
Wolff M, Bower DJ, Marbella AM, Casanova JE. US family physicians' experiences with practice guidelines. Family Medicine 1998; 30(2):117–121.
Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990; 113(11):852–871.
Wong JG, Feussner JR. Screening for colon cancer. Is it worth the expense? North Carolina Medical Journal 1993; 54(12):634–638.
Woo KS, White HD. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Pharmacoeconomics 1993; 3(3):192–204.
Woods KL, Ketley D. Utilisation of thrombolytic therapy in older patients with myocardial infarction. Drugs Aging 1998; 13(6):435–441.
Wu AH, Clive JM. Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain. Clin Chem 1997; 43(2):326–332.
Yen ST, Jones AM. Individual cigarette consumption and addiction: a flexible limited dependent variable approach. Health Economics 1996; 5(2):105–117.